This site is intended for US healthcare professionals

Congresses

The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

American Society of Clinical Psychopharmacology
May 28th – 31st 2024, Miami, FL
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted.
Schizophrenia
ENCORE POSTER
Key Characteristics of the Atypical Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for the Treatment of Schizophrenia
AUTHOR(S)

Leslie Citrome, MD, MPH1 ; Christoph U. Correll, MD2-4; Gregory W. Mattingly, MD5 ; Andrew J. Cutler, MD6 ; Amber R. Hoberg, NP, CRNP7 ; Peter J. Weiden, MD8 ; Bhaskar Rege, PhD9 ; James A. McGrory, PhD9 ; Martin Dunbar, PhD9 ; Craig Hopkinson, MD9 ; David McDonnell, MD10

Bipolar Disorder
Schizophrenia
ENCORE POSTER
Long-Term Safety and Efficacy of Olanzapine and Samidorphan: Results of a 4-Year Open-Label Study
AUTHOR(S)

Jacob S. Ballon,1 René S. Kahn,2 Martin Dunbar,3 David McDonnell,4 Christoph U. Correll5-7

Schizophrenia
ENCORE POSTER
Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen
AUTHOR(S)

Lauren N. Strand, PhD, MS1 ; Michael J. Doane, PhD1 ; James A. McGrory, PhD1 ; Alejandro G. Hughes, MPH2 ; John Lauriello, MD3